Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amplimexon plus Docetaxel in Metastatic NSCLC
NCT00697060Phase 2Withdrawn
- Sponsor
- AmpliMed Corporation
- Start
- Aug 2010
- Primary completion
- Aug 2011
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of imexon in non-small cell lung cancer (NSCLC), sponsored by AmpliMed Corporation. Planned start Aug 2010; status: withdrawn.
02
Drugs
imexon
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00697060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00697060.